How many insider declarations has Decheng Capital Global Life Sciences Fund IV, L.P. filed?

Decheng Capital Global Life Sciences Fund IV, L.P. has filed 3 public insider declarations with SEC (Form 4).

What is Decheng Capital Global Life Sciences Fund IV, L.P.'s role?

Decheng Capital Global Life Sciences Fund IV, L.P.'s reported role is not specified by the regulator across the filings.

Which companies does Decheng Capital Global Life Sciences Fund IV, L.P. report trades for?

Decheng Capital Global Life Sciences Fund IV, L.P. reports trades for 2 companies, including CG Oncology, Inc..

What is Decheng Capital Global Life Sciences Fund IV, L.P.'s declared buy vs sell volume?

Across the available history, declared buys total 7.0M€ and disposals 0.

← Executives ★ Sign in to follow

DC

Decheng Capital Global Life Sciences Fund IV, L.P.

·SEC (Form 4)

CG Oncology, Inc.Aardvark Therapeutics, Inc.

0

Total declarations

0

Companies

€7m

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Insider track record

Other

Disclosed buys

1

Disclosed sells

0

T+90 hit rate

0%

T+90 mean return

-10.9%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Discover the full record of transactions filed by Decheng Capital Global Life Sciences Fund IV, L.P.. Officer active across 2 companies, notably CG Oncology, Inc.. Cumulatively, 3 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €7m. Activity tracked since 29 January 2024. The latest transaction was filed on 29 January 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.

Companies and markets linked to Decheng Capital Global Life Sciences Fund IV, L.P.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

CG Oncology, Inc. (US)Aardvark Therapeutics, Inc. (US)

Declarations3 total

●

Decheng Capital Global Life Sciences Fund IV, L.P.

Executives14 Feb 2025Aardvark Therapeutics, Inc.

0SEC ↗

2,333,887 sharesCommon StockSEC:0000950170-25-023409:0

▲

Decheng Capital Global Life Sciences Fund IV, L.P.

Executives29 Jan 2024CG Oncology, Inc.

$8M29SEC ↗

400,000 shares@ US$19.00100.0% of flowCommon StockSEC:0001415889-24-010609:0

Canonical exit: 28 Apr 2024 (T+90)

●

Decheng Capital Global Life Sciences Fund IV, L.P.

Executives29 Jan 2024CG Oncology, Inc.

0SEC ↗

3,628,198 sharesCommon StockSEC:0001415889-24-002062:0

3 of 3 declarations

InsidersTradesSigma

← Executives ★ Sign in to follow

DC

Decheng Capital Global Life Sciences Fund IV, L.P.

·SEC (Form 4)

CG Oncology, Inc.Aardvark Therapeutics, Inc.

0

Total declarations

0

Companies

€7m

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Insider track record

Other

Disclosed buys

1

Disclosed sells

0

T+90 hit rate

0%

T+90 mean return

-10.9%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Discover the full record of transactions filed by Decheng Capital Global Life Sciences Fund IV, L.P.. Officer active across 2 companies, notably CG Oncology, Inc.. Cumulatively, 3 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €7m. Activity tracked since 29 January 2024. The latest transaction was filed on 29 January 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.